<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02992080</url>
  </required_header>
  <id_info>
    <org_study_id>9548</org_study_id>
    <nct_id>NCT02992080</nct_id>
  </id_info>
  <brief_title>Small Circulating RNA as Molecular Markers of Lung Disease in Cystic Fibrosis</brief_title>
  <acronym>MIRDIAMUCO</acronym>
  <official_title>Determination of Circulating miRNAs as Diagnostic Markers of Lung Disease in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to assess miRNAs expression profiles in the circuling blood of
      patients with cystic fibrosis and highlight &quot;signatures&quot; that could reflect the pulmonary
      status of patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this project is to study the circulating miRNA profiles in 40 patients with
      cystic fibrosis and 40 healthy individuals to assess whether these biomolecules could be used
      as markers of the pulmonary disease in cystic fifbosis. Moreover by comparing miRNAs
      expression level between Cystic fibrosis (CF) patients with severe (n=20) or moderate (n=20)
      pulmonary impairment, we want to assess whether some of these miRNAs may be used as markers
      for the severity of CF pulmonary disease. The identification of sensitive and early markers,
      from a non-invasive sampling could enable more effective and early treatment of CF patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of miRNAs expression between Cystic Fibrosis (CF) patients and healthy controls</measure>
    <time_frame>After blood collection: 2 years</time_frame>
    <description>Compare the distributions of miRNAs expression in blood samples of CF patients and to healthy controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assesment of miRNAs expression in Cystic Fibrosis Patients depending on the pulmonary status</measure>
    <time_frame>After blood collection 2 years</time_frame>
    <description>Compare the distributions of miRNAs expression in blood samples of CF patients with mild lung disease and CF patients with severe lung disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cystic fibrosis Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without fibrosis cystic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>miRNAs isolation from blood samples of patients and control</intervention_name>
    <description>Blood sample collection in specific PAXGene tubes</description>
    <arm_group_label>Cystic fibrosis Patients</arm_group_label>
    <arm_group_label>Patients without fibrosis cystic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Cystic fibrosis (CF) (MIM#219700) who are compound heterozygous or
             homozygous for CF causing mutations Healthy controls non -smokers and free pulmonary
             disease

        Exclusion Criteria:

          -  Participation or within the exclusion period of other clinicals trials Patients
             carrying mutations of clinical varying consequences or non CF-causing mutations

          -  smokers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline RAYNAL, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier University Hospital (CHU Montpellier) Montpellier University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline RAYNAL, PharmD, PhD</last_name>
    <phone>+33(0)411759864</phone>
    <email>caroline.raynal@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Magali TAULAN-CADARS, PharmD, PhD</last_name>
    <phone>+33(0)411759864</phone>
    <email>magali.taulan@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline raynal, PharmD,PhD</last_name>
      <phone>+33(0)411759864</phone>
      <email>caroline.raynal@inserm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Magali TAULAN-CADARS, PharmD,PhD</last_name>
      <phone>+33(0)411759864</phone>
      <email>magali.taulan@inserm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Caroline RAYNAL, PharmD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphael CHIRON, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle SERMET GAUDELUS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2016</study_first_posted>
  <last_update_submitted>December 9, 2016</last_update_submitted>
  <last_update_submitted_qc>December 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patient with Cystic Fibrosis</keyword>
  <keyword>Patient without Cystic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

